Ipca Laboratories Limited (IPCALAB) Earnings Call Transcript
August 14, 2026
Earnings Call Speaker Segments
Good day, everyone, and welcome to the Ipca Laboratories Q1 FY 2027 earnings conference call. Just a reminder that every participant line is in listen-only mode, and you'll have a chance to ask questions once the presentation wraps up. If you need help at any point during the call, just signal an operator by pressing star then zero on your touchtone phone. Please be aware that this conference is being recorded. I'll now turn the conference over to Mr. Nitin Agarwal from DAM Capital. Thank you, and over to you, sir.
Hello there, and thanks. Good afternoon to all of you, and a very warm welcome to the Ipca Labs Q1 FY 2027 earnings call, which DAM Capital Advisors Limited is hosting. Joining us today from Ipca Labs management are Mr. A.K. Jain, Managing Director, and Mr. Harish Kamath, Corporate Counsel and Company Secretary. I'll pass the call to Mr. Jain for his opening remarks, and after that we'll open the floor for questions. Please go ahead, sir.
Thank you, Nitin, and thanks to DAM Capital for putting this call together. The earnings call today, along with the discussion and the answers we give, may contain some forward-looking statements that rest on our present business expectations. These need to be looked at alongside the risks that a pharmaceutical business encounters. What we actually deliver financially in the future could turn out different from what is projected and perceived. You may apply your own judgment to the information shared during this call. Our domestic formulation business in Q1 FY 2027 achieved growth of 13%, reaching roughly INR 1,082 crores, compared with INR 961 crores in Q1 FY 2026. As of mid-June 2026, Ipca's ranking stayed consistently at about 16, according to IQVIA. Our market share edged up slightly to approximately 2.08%, versus 2.07% in mid-March 2026. The top six brands from Ipca are still among the country's top 300 brands. Ipca beat the IPM in both the chronic and acute segments. Growth in our chronic segment came in at about 17.2%, acute grew about 8.9%, and on an overall basis IQVIA has tracked our growth at roughly 11.7%. The export business overall posted growth of about 34% for Q1 FY 2027, reaching approximately INR 603 crores, up from INR 450 crores in Q1 FY 2026. Promotional branded markets within ROW markets grew about 16%, to INR 143 crores from INR 124 crores in the first quarter of the last financial year.
When you strip out the tender segment, the remaining business grew roughly 27% in Q1 FY 2027, reaching about INR 340 crores, compared with INR 268 crores in Q1 FY 2026. Our institutional generics arm posted growth of approximately 107%, coming in at around INR 111.75 crores versus INR 58 crores in Q1 FY 2026. Shipments valued at roughly INR 40 crores that had been slated for March actually went out in April, so this quarter the institutional business showed outstanding growth. The API business in Q1 FY 2026 grew almost 30%, to about INR 424 crores from INR 362 crores in FY 2026. For the first quarter of this financial year, nearly every one of our businesses turned in solid growth. Looking at consolidation, the total business rose about 21%, to INR 2,788 crores from INR 2,309 crores in FY 2026. During Q1 FY 2027 we encountered considerable uncertainty, major swings in material prices, delays in shipments, containers that simply weren't available, and a big jump in logistics costs, which continues climbing from July into August, and at certain destination sites such as South America, getting containers and shipping is very difficult.
So all in all, in spite of every one of these factors, we managed to produce stronger profitability. On a consolidated basis, EBITDA margins came in at 22.88% for Q1 FY 2027, up from 18.39% in Q1 FY 2026. That works out to a gain of nearly 4.49%. In absolute terms it is roughly INR 638 crores versus INR 425 crores in the prior financial year — a rise of almost 50%. For Ipca on a standalone basis, EBITDA margins rose to 26% in Q1 FY 2027, coming to around 23.82%, from INR 557 crores compared with INR 416 crore in the previous financial year, which is an improvement of almost 34%. Now that I've laid out the headline figures, I'd like to invite the participants to pose their questions.
Thanks a lot. At this point we'll open things up for questions. If you'd like to ask something, you can press star and one on your touchtone phone. Should you want to drop out of the queue, press star and two. We ask that participants use answers while posing questions. Ladies and gentlemen, we'll hold for a moment as the question queue builds up. Anyone who wants to ask a question can press star and one at this time. Those wishing to pose a question may press star and one on their touch-tone telephone. Our first question comes from the line of Rashmi Shetty with Dolat Capital. Please go ahead.
Yes, thanks for the chance to address this. Regarding India specifically, within the acute segment, our performance has lagged the market. What's driving that? And how are we performing overall in the India business, across both chronic and acute segments? What's the outlook for the India business for FY 2027?
On both chronic and acute, we've beaten the market. It's not the case that we've underperformed on acute. Market IPM growth stood at roughly 4.5%, and IQVIA reported our growth at 8.9%. Broadly speaking, within this market, I believe our anti-malarial segment fell by close to 24% during this quarter. That's among the reasons our performance isn't as strong as the overall picture, since malaria was present in this particular period. Turning to chronic, our IQVIA track came in at about 17.2%, while market growth was approximately 15.2%. Regarding overall business growth, let's say our internal growth — our pain management business, which covers rheumatoid arthritis and osteoarthritis, taken together — rose by roughly 13% for the quarter. The cardiovascular and anti-diabetic segment grew by about 17%. As I mentioned earlier, malaria dropped by nearly 24% this quarter. Malaria business is now becoming nearly insignificant. It accounts for barely 1% of our total business. Antibacterials delivered 1% growth. CNS delivered growth of nearly 19%. Our cough and cold segment delivered growth of about 9%. The derma business delivered growth of close to 17%.
Our urology segment has posted growth of roughly 25%, ophthalmology came in at about 17%, and the business overall grew close to 13%. The broader outlook also appears stronger, since market growth itself has begun to pick up, and the trend we observe is that chronic business growth rates in the market are quite healthy — and at this point we are delivering growth that keeps pace with the market.
So the 12%-13% guidance you gave before — that's still going to hold for this year, correct?
Right.
All right. Regarding the institutional segment, what level of normalized growth ought we to expect over the coming quarters? Or would it be preferable if you could provide it for the full year alone, along with where that acceleration is occurring, essentially.
As I mentioned, the significant growth this quarter stems solely from 40 crore worth of shipments that were meant to go out in March. Shipping delays and similar issues pushed them into April. These are all nominated shipments, so it isn't within our control. We simply hand over the goods and notify that the goods are ready for the buyer's nominee, and they collect them based on when shipping is available. What sometimes happens is that by the time they book the vessel and secure the permission to ship, along with the freight rate and all of that, either the ship has departed or the rate has climbed. So he has to begin again, and delivery ends up happening later. For that reason, the shipments slipped, and that's why there is exceptional growth. On the institutional business, we aren't seeking very high growth. It will stay in a single-digit kind of growth. The overall business may be somewhere around INR 260 crore to INR 300 crore. That's the range it will be in. We are not anticipating very high growth from institutions going forward.
Rashmi, ma'am, please go ahead with your question.
Allow me one final question, please. We've witnessed fairly solid growth in the generic segment. Previously, the U.K. business was dealing with certain supply problems. Have all of those now been sorted out, which would explain the nice uptick in growth we're seeing? And are we getting any traction in other geographies? If you could expand on that, I'd appreciate it. Also, what's the outlook for the full year for this piece as well as for the branded generic business?
To give you the overall picture, if you look at the generic business on a broad-based basis, the entire market has delivered solid growth. Turning to Europe, that business as a whole has posted roughly 70%, and the EU is really the main growth driver there. The business has gone from INR 53 crore to INR 137 crore, almost entirely — that's a significant increase coming from the EU. Our spending toward the U.S. is up about 8%. In Canada, we're seeing a slight decline. Broadly speaking, the generic business excluding institutions stands at around INR 268 crore, and it has reached roughly INR 370 crore for Ipca as a whole. Because of the institutions and the strong European growth, overall business growth came in very high.
Will we be raising our guidance for the generic business for FY 2027?
So at the start of the year, let's say we had provided guidance for business growth of roughly 12%-13%. But now, considering the upside we're seeing from the overall generic business, the India business is performing very well. Even the API business has delivered good growth. So the overall growth percentage may go from 12% to 13% to almost around 14% to 16% for the whole of the current financial year.
All right. That 14% to 16% will come mostly from your upgrading in certain portions of the guidance in the branded market and the generic market. Do you have any update on your Unichem Laboratories? That business is also doing very well on margin and in terms of strong revenue growth. Where do we stand there, and what growth and margin guidance do we give now?
Looking at Unichem overall in the first quarter, I'd say the U.S. business delivered growth of roughly 27%. That's mostly because the Unichem portfolio itself grew about 9%. The Ipca portfolio that they sell on our behalf in the U.S. has performed really well, and that's why we saw close to 27%. On its own, Unichem's portfolio came in at a growth rate of roughly 9%.
Alright.
Their Europe portfolio has posted growth of nearly about 3%. Brazil has delivered solid growth, and traction in Brazil is improving as well. So they grew by nearly about 52% this quarter, and they'll keep performing well in Brazil. The Acacia business, which is their ROW market business, has also roughly doubled during the quarter, from INR 8 crore to INR 17 crore. Unichem's API business has also begun moving up now, from INR 33, INR 34 crore to nearly about INR 58 crore. So that's an overall improvement of nearly about 73% in that business. So on the whole, Unichem has done well too where overall growth is concerned. Yeah.
You're still sticking with the outlook you gave last quarter, correct — 10% growth for the Unichem portfolio and a 13% EBITDA margin? Those stay intact, right?
Right. Regarding the Unichem guidelines, I'm not making any revision at this point. So let's watch how things perform over the next few quarters — we're putting in hard work to deliver additional growth, but let's see how it goes on the ground, and after that we'll revise the guidelines.
All right. Thanks a lot, sir, on my end. That’s all.
Thanks. We'll take the next question from Kunal at Axis Capital. Go ahead.
Good afternoon, and thanks for the chance to speak. Sir, first, regarding the U.S. business, if you wouldn't mind giving us some color on what we can expect over the next one to two years. Maybe some sense of how many launches there will be, both from Ipca stable and from Unichem as well. Also, you had talked in the past about how for some of Unichem's products, you are going to change the API source to Ipca. So some more color on the U.S. business would be very helpful, sir.
I'd say Ipca typically launches somewhere in the neighborhood of three to four products, and Unichem will come out with comparable types of products as well. So in a given year, I think you're looking at roughly seven to eight launches of that kind, counting Ipca and Unichem together. We've already gotten some of the product approvals for source changes. A few products are still in the pipeline. That effort is continuing. They're also putting a lot of hard work into, say, reducing costs on API, and those have been filed with FDA too — some are sitting on CB30 and some are on the fast basis — so getting those approvals may take a bit more time, but that work is ongoing. Yeah.
But sir, based on your baseline, is it reasonable for us to expect something like 20% or 30% consistent growth over the next few years?
Perhaps growth of roughly 15%, 16%, or 17% is achievable, though right now we're looking at the portfolio and other matters.
Sure, sir. Just one more question, sir. You talked about material costs rising significantly. So if you could perhaps quantify a little the kind of gross margin impact one might expect over the coming quarters. Is it fluctuating, or is it going up in one direction only? A bit more color would be helpful, sir.
It went up, then dipped a bit, then rose slightly again since petroleum prices are climbing, there are supply chain disruptions in places, some products are declining and others rising. Broadly, looking at the last financial year, we did grow in turnover terms, but it meant that overall material cost to sales fell by roughly 2%. In this quarter, when you look at it, we grew by roughly 21%, and my material cost also rose by 21%. So broadly, we lifted the EBITDA margin by nearly 2.4%, though for the most part that did not stem from savings on material cost overall. The saving on material cost is only 0.14%. Mostly, the EBITDA gain came about because turnover rose, so personal cost to sales dropped by nearly 1.41%, and manufacturing cost to sales — overall against revenue — declined by nearly 0.91%. On a consolidation basis, if you look, material cost is lower by nearly 1.35%. Personal cost is lower by nearly 1.95%. Manufacturing and other cost is lower by roughly 1.19%. So broadly, EBITDA on a consolidation basis improved by nearly 4.49% for the quarter.
But sir, my question is really more about looking ahead, since you mentioned that in July and August prices are rising once more. So do you expect there to be some margin pressure over the remaining quarters?
Nope, no pressure on margins at all. From what I can see, relative to the sales group, material cost is going to come down a little.
All right, that's helpful to hear. And sir, you brought up other expenses as well — shipping, containers, and logistics costs — so everything like that is already included in your guidance, correct?
Sure, we’ve factored that in, but look—freight rates in some places have tripled. For example, in South American markets, I believe for containers, freight was roughly 3,000. Now it’s roughly 9,000 to 10,000. And even getting space is hard. As for the U.S., reefer containers used to be available at about 7,000 to 7,500. Today it’s roughly 12,500 to 3,000. Even European containers, which were 3,000, are now around 5,500. So rates are rising everywhere.
Understood.
Yeah, we factored that into the shipment.
Understood, sir. If I may, just one additional question. Regarding the India business, could you share the sales force strength and what the expansion plans are?
We're at roughly 7,000 people now, with the medical reps included, and the expansion plan has already been finished. So that 7,000 figure covers it. Around the middle of the year, we might add roughly 200 more people across some of the new divisions we'll be launching this year. That won't raise the number much, though—only by about 200.
Understood, sir. That was quite useful, sir. Thanks, and best wishes.
Thanks. Our following question comes from Mohit with Oculus Capital. Mohit, go ahead — are you there?
Hi there.
Yes, sir.
Yes. Sir, my question is about your associate company, Lyka Labs. We put money into this company in FY 2022, and then also invested through the primary route up until FY 2025. Now this company's revenue hasn't grown, and even the EBITDA has turned negative. So are there any plans to revive this company? What is going on there with the lyophilized injection? What are we doing there?
So, let's take it that they're developing three separate types of businesses. The first one is the animal health business. They have a lot of injectables that go into animal health. They've done solid work when it comes to building that business. Second, they've launched the critical care business, meaning they sell directly to hospitals and so on. Previously, most of their business was coming from B2B supplies to other pharma companies. That business is declining, and their own promoted business is now rising. That's the second business, and third, they have a lot of products related to IVF. That part has also begun performing well, and they've added roughly a significant number of field force over the last two years, and that is where they're incurring the cost. Some of these are near breakeven, and some of these divisions are still below breakeven. So that cost is also part of their overall. Overall, I think we're hopeful that Lyka will do well going forward. They're on the right path.
Alright, sir, just one suggestion. When the results come out, if you could issue some kind of press release explaining what’s happening there, that would help a lot — because it’s really hard to figure out what that company is doing, since it’s also a listed company. If a press release could be provided with updates on what’s going on there, that would be very helpful. Thank you, sir. All the best.
My understanding is that the press release has been issued by them this year.
All right, I wasn't able to view that. All right, thanks.
Sure, we’ll get that over to you.
Thanks. We'll take the next question from Shilpa at Lotus Wealth. Go ahead.
Hi there. I have a question about Unichem. Sir, are the gains in our gross margin coming from rupee depreciation boosting realizations, or has Ipca begun supplying the API?
The amount of Ipca supply going to Unichem is barely anything. There's one product, I believe, for which they've now placed the order, since a source change took place. For one thing, their overall cost reductions have been solid when it comes to their own captive API production. That has likewise led to some margin improvement overall on their side.
Alright.
Europe is performing nicely for them. Improvements in margins across the business as a whole, plus Brazil—which had been running losses—are now turning positive, and that operation should keep getting better too. Those factors are what's driving the stronger margin overall. As they get going, they have an entire program aimed at registering new products across all these markets, including Europe, Australia, New Zealand, Canada, Chile, and the rest of them. Once those registrations begin to arrive, I believe the business profile of this company will shift as well. Right now it's largely the U.S., a market where margins are perpetually squeezed. In these markets, once the product mix and the broader market mix get better, Unichem's profitability will get better too.
All right, sir. For this quarter, there isn't really any rupee depreciation impact, correct?
There's also the depreciation of the rupee. Take total turnover — of that 21% growth, only 5% comes from the rupee's decline. The dollar is up by roughly 11% versus the first quarter of last year. At the same time, that has pushed our material cost higher as well. Still, it has benefited the overall margin. Material cost has risen too, since, say, many of your inputs are priced in dollar terms, and those costs have gone up as well.
Alright.
That applies just to the net 25%, since material cost to sales sits at roughly 25%. So on 25% of that cost, your depreciation cost has been removed, but the remainder has come through in margin.
All right, sir. Thank you.
Thanks. Prior to moving on to the next question, we'd like to remind everyone that you can press star and one to ask a question. Our next question comes from Tushar at Motilal Oswal. Please go ahead.
Thank you for the chance to ask. Sir, I didn't catch the EBITDA margin guidance you may have given for FY 2027 — first of all. Could you share that again, please?
We started the year with EBITDA margin guidance of about 22% on a consolidated basis. Given the stronger performance, I'd say overall EBITDA margins could stay near 23%. So I'm raising the guidance by 1%, yeah.
Okay. Sir, second point — although there are swings in raw material costs, the rupee's depreciation ought to be enough to counter any movement in what you pay for raw materials. In fact, would it be fair to assume that the gain from the rupee weakening is considerably larger than the raw material price swing, and so it should lead to an improved gross margin?
Take material cost to sales at 25%. Within that, a great deal of your Indian ingredients, plus other ingredients, are imported. Plenty of additional costs are tied to dollar terms as well. Freight, for instance, is denominated in dollars. A lot of testing materials and many such items are also in dollar terms. Numerous machine parts for imported machines, along with testing equipment and the like, relate to dollar terms too, so their maintenance contracts and similar arrangements are linked that way as well. We have a very large field force across international markets. Their salaries are paid in dollar terms too, given promotional markets and everything of that sort. It isn't just raw materials that are affected — other things are being affected as well. For the promotional market, we operate many non-trading offices in various international markets. So the cost there is also rising because of the USD. Even with, say, the cost increase and all of that, overall, thanks to depreciation, to the extent of your margins and some Indian costs, that cost isn't moving up, and that's why you're seeing a significant improvement in your overall manufacturing and other expenses.
Understood.
Sales have risen, though that expense has decreased.
Understood. And what’s fueling the expansion within the Europe segment? Are new product launches the driver? Or is it share gains in the market?
We’ve also got new product launches in the mix. Both the European and U.K. businesses — and the European operation as well — have performed very strongly.
Is the funnel stemming from Unichem's portfolio beginning to show up in Ipca's Europe business?
Nope.
At what point do we expect that to begin, sir?
This is going to take a while, since they've begun submitting filings in those markets. Approvals are still pending on our side, and from the point of filing it generally takes roughly 1.5 years for the approvals to arrive. Right, they do have a substantial number of programs being filed across the various markets. As those approvals begin to come through, Unichem's margin profile will begin to shift as well.
Got it, sir. And one last thing — aside from the product transfers, when are we planning to begin new filings for the U.S. market?
No, that's already in place. For Ipca, I figure 4 to 5 filings will occur each year.
Understood. Many thanks. That's all I have.
Thanks. The following question comes from Kartick Bane at Bajaj Life. Please go ahead.
Appreciate the chance to ask. Since the Indian field force expansion is mostly finished and profitability is getting better too, would you put the extra cash flow toward acquisitions or some capacity expansion, or would the emphasis be more on filings and launches?
We'll also need that capacity expansion, and it's happening right now, since a lot of capacity will be required for the European markets and the U.S. market. At this moment, we're building up capacities at our Silvassa for all these controlled releases and all the extended release kind of formulations. Traditional CapExs are going on. Biotech is one area where CapExs are also going on, in terms of further increasing R&D investments, R&D assets, and at the plant level, those kind of CapEx are there as well. On the API side too, we're building up new plants because we're running out of capacities at Ratlam. New plants are being built up at the Dewas site and also at Wardha for intermediates and all. Some of the investments are also going on for converting the existing intermediates into more continuous process kind of processes. Those investments are also there. Largely, I think, almost around INR 700 crore to INR 800 crore in the current year will go on the CapEx side itself. Yeah.
Appreciate it.
Thanks. Our next question comes from Aditya Chheda, who's on the line from InCred Asset Management. Go ahead, please.
Hi, Pooja Sanghi here. Thanks for giving me the chance. We get that the pricing was locked in earlier, and with the rupee having depreciated since then, your realizations in rupee terms should have risen. Still, from what I recall of the past, whenever situations like this come up, the dollar prices tend to be renegotiated downward again. If that does happen, sir, how long do you think the currency tailwind and the higher gross margin will show up in our statements — another two quarters, or another year?
I don’t believe there are any renegotiations of that kind in which prices would be lowered. No. Instead, we’re raising prices across the board, since your costs are rising as well. Every other cost is climbing too. There are no decreases, and prices are mostly moving in one direction—upward—rather than falling.
All right, thank you, sir.
Thanks. Anyone who wants to ask a question, please press star and 1 at this time. If you'd like to ask a question, press star and 1 now. We have a follow-up question from Kartick Bane at Bajaj Life. Go ahead.
Hi there, and thanks again for the chance to follow up. Would it be possible to break out the domestic growth into its price and volume components, along with the contribution from the new product launches?
On the whole, I'd say volume growth comes in at nearly 5%. Pricing adds roughly another 4.5% to 5%, in my view, and new product launches probably contribute about 2% or thereabouts. That puts total growth at approximately 13%. Yeah.
I appreciate that.
When you look at the industry as a whole, our volume growth comes in above it.
Thanks. Our next question comes from Rashmi Shetty at Dolat Capital. Go ahead.
Yeah, thanks again for the chance to follow up. Just one quick housekeeping item. This quarter, we saw interest cost come down versus the prior quarter. If you could share a few thoughts on the total gross debt figure and on whether any repayments have been made or anything along those lines.
During the previous fiscal year, we carried roughly close to $50 million in dollar-denominated loans, and those were fully paid back before March arrived. Actually, prior to the onset of this dollar depreciation, we had pretty much prepaid all of our dollar borrowings. We don't carry that type of debt on the books anymore. Right now, debt stands at approximately INR 193 crore in the books. That figure represents long-term debt. Our working capital debt is zero. I believe by the end of this year, we will be left with INR 70 crore of term loan debt outstanding, and that amount will be entirely repaid during the following financial year. So in effect, we hold more cash on the books than our total loans. As things stand, loans are barely about INR 193 crore.
So from that INR 193 crore, you're indicating that INR 70 crore will also be repaid by you.
No. By the time we reach year-end, INR 70 crore will be balanced, since that loan carries a rate far cheaper than what the market currently offers.
Alright.
I make more from the mutual fund instead of. Why would I pay it? I'll pay on the due date. Yeah.
All right. There are no short-term borrowings on our books.
Zero. Yeah.
So interest cost should also come down in the quarters that follow, is that right?
Right. Interest cost is going to be barely anything. We’ll be earning more than decline.
All right. Yes, got it, sir. Appreciate it. That's all from me. Okay.
Thanks. Our next question comes from Ankeet Pandya at Baroda BNP. Go ahead, please.
Yeah, hi. Thanks for the chance to ask. Just a single question. Could you provide some guidance on the FY28 figures, specifically regarding top line growth and EBITDA margin?
Regarding this current financial year, we've already provided the guidance. The revised guidance calls for growth of roughly 14%-16%. We raised it from the earlier 12%-13%. And for consolidated EBITDA margin, 22%-23%. Overall, we've bumped that up by 1%.
Sir, my question is about FY28.
Regarding the 2028 guidelines, we'll provide those during quarter 4.
All right, that's fair. Fine. Okay. That's all I have to say. Thanks.
Thanks. Anyone who wants to ask a question, please press star and one at this time. If you'd like to pose a question, press star and one now. Our next question comes from Saion Mukherjee of Nomura. Go ahead.
Good evening, and thanks for taking my question. I just have one question about EBITDA margin for your consolidated business and for Unichem Laboratories. If you factor in all the effects of Unichem Laboratories synergies unfolding over roughly the next 3 years, along with the business scaling up in the U.S. and other markets and India growing, where do you see EBITDA margin settling from a somewhat medium- to longer-term view, for both Unichem Laboratories and Ipca Laboratories as a whole?
If Ipca's margin — currently sitting at roughly 26% — were to rise, a level of nearly 30% is achievable. On a consolidated basis, overall EBITDA margins in perhaps 2 or 3 years could reach about 25%–26%, since by then all those other subsidiary companies will be performing very well too.
Okay. Sir, when it comes to the main investments, which investments or new initiatives would Ipca be looking to take on across the coming two to three years, so to speak? If there happen to be any plans or thinking around inorganic or organic moves, some major investment plans.
At the moment, the bulk of our investment is going more toward the biotech side. We now have roughly seven candidates in the pipeline. We're working on a larger number as we speak. R&D now has the capacity to handle at least about three to four products each year. I believe two products have already gone through their engineering batches, and the results line up perfectly with our expectations. Validations are underway, I'd say, and a substantial amount of investment is going to go into clinical trials for all of these biosimilars. We're aiming at all global markets, and for most of the products the known titer values are effectively double, or beyond, what's currently known in the market. We expect to perform well, and a good deal of further investment is going to flow into biotech. In the current year as well, we'll be putting in close to INR 100 crore more toward building up the piloting facilities plus additional R&D investment in biotech. Plenty of that investment is taking place right now. Perhaps in one or two years' time, we might have to expand further the capacities we've built up on the biotech side. That will mean another additional investment down the road.
So, sir, regarding the EBITDA guidance or the EBITDA expectation you have, you're factoring in these clinical trials and these investments on
Yeah.
Biotech.
That's what we're factoring in. Since no revenue is going to come in during the next two years, because by the time the clinical trial wraps up, so all of that is what we're factoring in.
Okay. Sir, could you shed some light on these products? You seem to be saying your yields are far superior to what the market offers today. Regarding these seven biosimilars, two of which are perhaps somewhat more advanced, are they older products, or are they products whose patents will expire and you'll be in the first wave in the market? And if you could give some color, some sense of what kinds of products you're working on.
For the most part, these are older products. However, there’s one product that we’re perhaps aiming at around its patent expiry, and that one is a very large product. The majority of the remaining products have already lost patent protection.
Okay, so you're saying that in 2 years we'll begin to see it — meaning that in FY29 and FY30, revenue will start coming in from biosimilars.
Right, since we first need to manufacture your API, after that comes formulations, then validating those formulations, followed by stability work, and then we move on to clinical trials. All of those steps are happening at the same time, yeah.
All right. Since these are global trials, does that mean you'll be filing in the U.S., in Europe, and outside those markets as well?
So all together, these trials are global in scope. We've already talked with regulators in Europe, the U.K., and also the U.S. about every one of the clinical trial protocols and so on. Each protocol aligns with all of those regulatory agencies.
So the filing takes place next year, correct? If a launch has to occur in fiscal 2030, then in fiscal 2028 you'd be submitting your initial filing. Would that be a fair assessment?
I think this year, practically the first thing that happens is validations of those products, and after that, formulations plus development and stability charging will take place this year. Somewhere around the middle of next year, I think the initial stability results will come in, and after that, since we have already obtained those kinds of approvals by then, we will begin the clinical work. Now clinical work is significantly reduced. We also have the phase III waiver from European authorities and from the U.S. as well. So only the initial work needs to be done. The cost has also come down significantly now because RLD is not required for phase III. So the RLD cost becomes very high. Those exemptions have already come. Looking into biosimilarities and other parameters and results, what we have submitted to the various regulatory agencies. So overall, I think clinical things will start happening from the next financial year.
All right, thank you, sir.
Thanks. Yeah.
Thanks. That was the final question for today. At this point, I’ll hand the conference back to management for closing remarks. Over to you, sir.
Yes. Thanks a lot to everyone who joined. Thank you. Madam, we’re ready to end this call now.
Yes, sir. That brings this conference to a close on behalf of DAM Capital. We appreciate your participation, and you can go ahead and disconnect your lines now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Ipca Laboratories Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Ipca Laboratories Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.